Antiverse: Designing Antibodies For Challenging Targets

Antiverse is a biotechnology company specializing in the design of antibodies for challenging drug targets using a generative AI platform. Founded in 2017, Antiverse leverages state-of-the-art machine learning and structural biology to accelerate the discovery of antibodies for difficult targets, such as G-protein-coupled receptors (GPCRs) and ion channels. The company’s platform uses next-generation sequencing and phage display techniques to model antibody-antigen interactions, significantly reducing the time and cost associated with traditional antibody discovery.

Key features include:

Antiverse is ideal for biotech and pharmaceutical companies seeking to develop novel antibody-based therapies for challenging targets.